Citrus aurantium for blood sugar balance -
The activities of superoxide dismutase SOD were increased in liver. The liver histological damages of experimental diabetic mice treated with C. aurantium extract were abated in comparison with the experimental diabetic mice under light microscope observation.
Conclusion: It was suggested that the extract of C. Download citation: BibTeX RIS EndNote Medlars ProCite Reference Manager RefWorks Send citation to:. Ravanshad S, Naserollahzadeh J, Sovaid M, Setoudehmaram E. Effect of Sour Orange Citrus Aurantium L.
Juice Consumption on Blood Glucose and Lipid Profile in Diabetic Patients with Dyslipidemia. Abstract: Views. Abstract Introduction: Sour orange is known as an herbal plant in folk medicine.
Previous studies indicate a protective relationship between the consumption of citrus fruits or juices and risk of some chronic diseases. Objective: In this study, the effect of short-term consumption of sour orange juice on blood glucose and lipid profile of diabetic patients was evaluated.
Materials and Methods: In a clinical trial study before and after , thirty-five 10 men and 25 women dyslipidemic diabetic patients without nephropathy with mean age Alternatively, a formulation may comprise a patch or a dressing such as a bandage or adhesive plaster impregnated with active ingredients and optionally one or more excipients or diluents.
Formulations suitable for topical administration in the mouth also include lozenges comprising the active ingredient in a flavored basis, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert basis such as gelatin and glycerin, or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.
Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations containing in addition to the active ingredient, such carriers as are known in the art to be appropriate.
Formulations suitable for nasal administration, wherein the carrier is a solid, include a coarse powder having a particle size, for example, in the range of about 20 to about microns which is administered in the manner in which snuff is taken, i.
Suitable formulations wherein the carrier is a liquid for administration as, for example, nasal spray, nasal drops, or by aerosol administration by nebulizer, include aqueous or oily solutions of the active ingredient. Formulations suitable for parenteral administration include aqueous and non-aqueous isotonic sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents, and liposomes or other microparticulate systems which are designed to target the compound to blood components or one or more organs.
The formulations may be presented in unit-dose or multi-dose sealed containers, for example, ampoules and vials, and may be stored in a freeze-dried lyophilized condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use.
Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.
Preferred unit dosage formulations are those containing a daily dose or unit, daily subdose, as herein above recited, or an appropriate fraction thereof, of a drug ingredient.
It should be understood that in addition to the ingredients particularly mentioned above, the formulations of this invention may include other bio-active agents conventional in the art having regard to the type of formulation in question.
For the purpose of illustration only, such additional bio-active agents include, but are not limited to sulphonylureas, e. chlorpropamide the trade name: Meldijan, etc.
and biguanides which includes, e. phenyl-ethyl-biguanide trade names: Phenformin, DB-Comb, etc. as well as dimethyl-biguanides trade names: Gluchopage, etc. In yet a further embodiment, additional agents suitable of oral administration may be included in the compositions and formulations, e.
The extract, fraction, compound or composition comprising one or more of the same, may also be presented for use in the form of veterinary formulations, which may be prepared, for example, by methods that are conventional in the art.
This invention further provides a method for screening for a therapeutic agent for treating or ameliorating the symptoms associated with abnormal blood glucose, e.
In one aspect, the patient is suffering from diabetes Type II. The assay can also be used to screen new or alternative formulations or combinations of the extract with another active agent or therapeutic.
The screen requires a the administration of the potential agent to a suitable animal model and b administering an effective amount of the extract, or a pharmaceutically acceptable composition containing the extract, to another suitable animal. The biomarkers of the therapeutic response of the animal s of step a to those of step b are compared.
If any agent of step a provides a therapeutic response that is the same or similar extent as the model of step b , it is a therapeutic agent for treating or ameliorating the symptoms associated with abnormal blood glucose in an animal.
Suitable animal models include, but are not limited to the animal model described in Experiment No. or a human patient, e. Also provided is the use of the extract in the manufacture of a medicament for the treatment of diabetes.
A kit for treating or ameliorating the symptoms associated with abnormal blood glucose, e. The kit includes a therapeutically effective amount of the extract and instructions for use. The kit is useful to treat disorders selected from the group consisting of Type II diabetes, abnormal steraroyl-CoA desaturase activity, hyperphagia, abnormal lipid mobilization, abnormal fatty acid profile from the eye of the subject, ulcers and glucosuria.
The following examples are intended to illustrate, but not limit the invention. Lipids constitute a major part of living cells where they provide the physical barrier that compartmentalizes cells and serve as a major storage form of energy in the liver and adipose tissue.
Membrane lipids do not just form an inert framework for cells. Rather, fundamental roles are now recognized for membrane lipids and their bioactive derivatives in cell function, especially in the responses of the cell to external stimuli from hormones, neurotransmitters and growth factors.
It is therefore not surprising that alterations in membrane lipid composition have been associated with specific disease conditions such as cystic fibrosis Freedman et al. Vessby B. However, there are conflicting reports in the literature as to the extent of the alterations and as to which tissue or organs best manifest the modifications.
While increases in the saturated fatty acid SFA and the lower molecular weight polyunsaturated fatty acid PUFA contents have been associated with altered skeletal muscle insulin responsiveness in man, Clore et al.
Arachidonic acid and a lower linoleic acid content in serum of diabetics as compared to samples taken from healthy controls. In order to establish the status of some of the parameters associated with lipid homeostasis in Type II diabetes model mice, the fatty acid FA content of tissues implicated in the pathophysiology of diabetes in mice was investigated.
The tissues investigated for their FA profiles include adipose tissue, eye, liver, pancreas and skeletal muscle. The results show that while there was an accumulation of lipids in most of the different tissues from the obese mice, there was selectiveness in the deposition of lipids in the adipose tissue, eye and muscle of the diabetic mice, and suggested increase in stearoyl-CoA desaturase activity in the latter two tissues.
The study was performed under the guidelines approved by the Danish Animal Care and Use license. The animals were purchased from Bomholtgaard Breeding and Research Centre Ltd.
The animals were kept in groups of mice per cage, maintained on Altromin standard maintenance diet and housed in a room kept at 25° C. with a 12 h dark and 12 h light cycle. When the animals were 23 weeks old, they were fasted overnight.
On the next day, the animals were weighed, ether anaesthetized and blood samples were collected by orbital puncture, before the animals were sacrificed. The blood samples were allowed to clot at room temperature about an hour and cleared serum samples were collected after high-speed centrifugation g at 4° C.
for 30 min. Missouri, USA. Briefly, the apparatus was fitted with a 60 m fused silica capillary column SP and the injector and detector temperature were at ° C. The carrier gas was helium. The initial oven temperature was 70° C. for 0. The activities of selected enzymes involved in fatty acid biosynthesis were estimated as the product to precursor ratios of the percentages of the individual fatty acids.
The estimated fatty acid-related metabolic processes included the delta9 or Stearoyl-CoA desaturase activity estimated as the ratio of oleic acid [C n-9 ] to stearic acid C ratio, and delta6 desaturase that was calculated as the ratio of the sum of γ-linolenic acid LNA, [C n-6 ], dihomogamalinolenic acid DGLA, [C n-6 ] and Arachidonic acid AA, [C n-6 ] to linoleic acid [C n-6 ].
The values are expressed as mean±standard errors. Statistical differences in the data were tested using ANOVA non-paired t-tests in Microsoft Excel. The body weights, serum insulin and glucagon levels from the mice are presented in Table 1.
There was no significant difference between the mean body weight of the diabetic mice and their lean counterparts. Genetically Obese and Diabetic Mice Tissues Differ in How Monounsaturated Fatty Acids are Accumulated.
The relative amounts of the major classes of fatty acids for the adipose tissue, eye, skeletal muscle, pancreas, liver-triacylglyceride liver-TAG fraction and liver-phospholipid liver-PL fraction from the different mice are presented in FIGS.
Generally, there was an increase in the total fatty acids and in particular SFA and MUFA in the tissues from the obese mice, as compared to that in both the lean and diabetic mice tissues. Thus, with the exception of the eye, significant increases in SFA and MUFA accumulation were observed in the obese mice tissues in comparison with values in the lean mice.
Interestingly, the genetically diabetic mice only showed a significant increase in FA accumulation especially MUFA in adipose tissue, the skeletal muscle and in the eye, when compared to the FA content in the lean mice tissues FIG.
In line with the above observations of MUFA accumulation, there was an increase in the calculated stearoyl CoA desaturase activity in most of the tissues from the obese mice FIGS.
For the diabetic mice, a significant increase in delta9 desaturation was only associated with the eye and skeletal muscle, which also had a marked accumulation of MUFAs see above.
Genetically Obese and Diabetic Mice Differ in How and in What Type of Polyunsaturated Fatty Acids are Accumulated in Tissues. While both the long and short chain forms of the PUFAs were accumulated in the obese mice tissues, the increase in the PUFA fraction in the diabetic mice muscle was mainly due to an accumulation of the short chain LA and alpha-linolenic acid FIG.
The reduction in delta6 desaturation could not be verified with an estimate of the delta4 desaturation calculated as the ratio of DHA [C n-3 ] to docosapentanoic acid DPA [C n-3 ], as several of the tissues from the diabetic mice lacked detectible levels of DPA.
However, the reduction in delta6 desaturation does coincide with significant reductions in DHA levels in the diabetic mice. In the obese mice, reductions in estimated delta6 activity were also calculated for the pancreas and liver-TAG fraction, while an increase was predicted for the adipose tissue and the liver-PL fraction FIGS.
The liver and adipose tissue constitute the major tissues for storage, processing and distribution of caloric fuels in mammals. Under normal conditions, there is a dynamic interplay between these and other tissues in the body that is highly responsive to certain hormones and co-factors, and ensures that mammalian tissues maintain a constant flow of energy-rich fuels despite intermittent fasting periods.
Type II diabetes or NIDDM results from a malfunction in the body's energy metabolism. The metabolic disturbances characteristic of NIDDM are increasingly being closely linked with alterations in lipid metabolism and obesity. Vessby New Eng.
Obesity is characterised by an increased accumulation of tissue lipids. Thus, the liver in severe mice diabetes appears to be spared against lipid accumulation.
Instead, the excessively generated MUFA is deposited in other non-adipose tissue, such as the eye and muscle see Table 2. Saturated fatty acids such as palmitic acid C and stearic acid C are synthesised in mammalian cells by the enzyme complex, FA synthetase FAS which uses the building blocks generated by the rate limiting enzyme, acetyl CoA carboxylase.
Enoch et al. However, in the high fat-diet that is common in most developed nations, some of the excess fat that is consumed is not catabolized, but simply stored in tissues.
Schmid et al. In this study, the estimated stearoyl-CoA desaturase activity was enhanced in the tissues with the exception of the eye from the obese mice.
In the diabetic mice, the increase in stearoyl-CoA desaturase activity was only associated with the eye and muscle namely in two of the tissues with increased MUFA accumulation. A central role for the enzyme in FA accumulation in obesity and in the development of Type II diabetes has been confirmed by the finding that the loss of one of the two mice SCD genes led to a reduction in body adiposity and resistance to diet-induced weight gain.
Ntambi et al. USA Rahman et al. Indeed the anti-Type II diabetes drugs, thiazolidinediones have been shown to exert part of their anti-diabetic effects via the PPARγ receptor by repressing SCD1 gene expression.
Kurebayashi et al. One of the long-term complications associated with NIDDM is poor wound healing. Today Essential fatty acids EFAs are important precursors for several eicosanoids and docosanoids that have pro-inflammatory and anti-inflammatory effects, respectively.
Hence, the alterations in the EFAs in the two NIDDM model mice were examined. In adult humans, insulin resistance in obesity and diabetes has been associated with relatively low proportions of the long chain PUFAs in skeletal tissue Borkman et al.
The biosynthesis of the long chain essential PUFAs from LA and alpha-linolenic acid in mammalian cells is driven by the delta6 and delta5 desaturases in a series of enlongation and desaturation steps. In the absence of insulin as is the case in untreated type I diabetes , both enzyme activities are down regulated.
Brenner Prostaglandins Leukot. Fatty Acids The condition is corrected on administration of insulin. Mercuri et al.
Although the activity of the enzymes have been well studied in type I diabetes, there is a paucity of data concerning their levels and activities in Type II diabetes. Furthermore, the lack of distinction between triacylglycerol and phopholipid fractions in most of the tissues analysed here makes it difficult to ascertain whether the increases in LA or alpha-linolenic are simply due to increases in triacylglycerol that favours accumulation of the short chain PUFAs.
Nevertheless, the alterations in the tissue content of EFAs in Type II diabetes can have some far reaching effects for the prognosis of Type II diabetes.
On the one hand, the long chain PUFA DHA that is scarce in severe NIDDM, is one of the main precursors for docosatrienes and resolvins that are beneficial for the resolution of both acute and chronic inflammation Hong et al. Calder Ann. On the other hand, a lipid based-molecule derived from LA by the action of lipoxygenase-1, S-hydrocyoctadecadienoic acid has been shown to be an apoptotic agent.
Shureiqi et al. USA ; Nixon et al. Taken together, the reduction in DHA combined with the increase in LA might contribute to enhancing some of the long-term complications of diabetes associated with the eye and in poor wound healing in skeletal muscle.
Recently, Brenner and associates Brenner et al. FA metabolism is cell-specific and the both the stearoyl CoA desaturase and delta6 desaturase activities considered in this study are estimates. It is therefore interesting to determine and compare the actual levels of expression and activities of the enzymes involved in the lipid homeostasis in tissues taken from the 3 groups of C57BL mice.
There were clear differences in lipid contents and composition in the tissues from the lean, obese and diabetic mice based on the same C57BL-genotype and fed the same diet.
Thus, with the exception of the eye, there was an accumulation of SFA and MUFA in all tissues from the genetically obese mice. The liver was spared the lipid accumulation and fatty acids-build up of the MUFA subclass was restricted to the eye, adipose tissue and skeletal muscle.
Both the mild and severe forms of NIDDM were associated with PUFA accumulation in the skeletal muscle, although the short chain PUFAs were predominantly responsible for the increases in severe NIDDM.
These distortions in the tissue lipids in Type II diabetes may define the pathophysiology of the disease. Experiment No.
Plant material and preparation of the Rauvolfia - Citrus infusion. A combination of washed dried foliage total weight, g was arranged in alternate layers with quartered whole citrus fruits total wet weight 2 kg , in a large aluminium pot.
The plant material was then covered with 8 liters of tap water, brought to the boil, and allowed to simmer covered, at low heat for 1 h. The resulting golden coloured fluid was cooled to room temperature and filtered through coarse filters.
The total yield was typically 7. The pooled plant extract was freeze-dried and the yield was typically 12 g dried extract from 1 liter. The mice are characterised by obesity, hyperphagia, temporal hyperinsulinaemia, degeneration of the pancreatic β-cells with age and hyperglycemia.
Due to the insulin resistance observed in these mice, they are considered models of Type II non-insulin dependent diabetes. The db gene has been identified as coding for one of the different mice forms of leptin receptors expressed in the hypothalamus. Lee et al. Leptin is a hormone secreted by adipocytes that has pleiotypic effects on a number of body systems including reproduction and metabolism.
Chehab et al. A total deficiency in leptin or resistance of the body to the effects of the protein can lead to the development of severe obesity.
Ahima et al. During treatment, both test and control animals were placed on calorie restriction by being fed with the carbohydrate and fat deficient Altromin C diet. All the animals were purchased from Bomholtgaard Breeding and Research Centre Ltd.
Citrus aurantium for blood sugar balance of Guilan Boood of Medical Sciences Journal Seed-tasting events Guilan University of Medical Sciences P. Box:Iran. Email: medjour gums. Thu, Feb 15, فارسی [ Archive ]. Remember me Create Account Reset Password.Citrus aurantium for blood sugar balance -
Thu, Feb 15, فارسی [ Archive ]. Remember me Create Account Reset Password. Volume 15, Issue 57 JGUMS , 15 57 : Back to browse issues page. Download citation: BibTeX RIS EndNote Medlars ProCite Reference Manager RefWorks Send citation to:. Ravanshad S, Naserollahzadeh J, Sovaid M, Setoudehmaram E.
Effect of Sour Orange Citrus Aurantium L. Juice Consumption on Blood Glucose and Lipid Profile in Diabetic Patients with Dyslipidemia. Abstract: Views. Abstract Introduction: Sour orange is known as an herbal plant in folk medicine. Figure 4 shows the effect of perception on the symptoms of diabetes multiplication, following symptoms.
The grouping of the X axis is shown in FIG. 도 5 는 당뇨병의 증상인 다뇨 현상의 개선에 지각이 미치는 영향을 보인다. 본 발명은 당뇨병치료용 조성물과 건강보조식품에 관한 것으로, 보다 상세하게는 지각을 포함한 당뇨병 치료용 한방약 복합제제, 건강보조식품 및 그 조제방법에 관한 것이다. The present invention relates to a composition for treating diabetes and health supplements, and more particularly, to a herbal medicine complex preparation for treating diabetes, health supplements, and a preparation method thereof.
한국인의 당뇨병 유병율은 최근 10년 사이에 급증하여 사망요인 제4위를 차지하고 있다. 당뇨 환자는 호르몬 불균형으로 인해 탄수화물, 단백질, 지질대사가 비정상적으로 진행되어 고혈당과 고지혈증을 나타내게 되고, 결국 심순환계 질환과 신경장애를 비롯한 합병증을 초래하게 된다. 당뇨환자는 중성지방 및 콜레스테롤 농도가 증가하고 HDL-콜레스테롤이 감소하는 등 지질대사에 이상이 일어나 심순환계 합병증 발생의 위험요인이 되며 당뇨환자의 주요 사망요인이 된다.
당뇨병의 치료법으로는 일반적으로 약물요법과 식이요법 및 운동요법을 병행하는데, 치료목표는 지 속적으로 이상적인 혈당을 유지하여 당뇨병성 합병증을 예방하고 지연하는 것이다. 그러나 현재 당뇨병은 완치법이 확립되어 있지 않으므로, 고혈당과 고지혈증을 개선할 수 있는 약물과 식품에 대하여 지속적인 연구가 요망되고 있다. The prevalence of diabetes among Koreans has risen rapidly in recent decades, making it the fourth leading cause of death.
Diabetes patients have abnormally advanced carbohydrates, proteins, and lipid metabolism due to hormonal imbalance, resulting in hyperglycemia and hyperlipidemia, resulting in complications including cardiovascular disease and neurological disorders.
Diabetes patients have increased metabolism of lipids such as increased triglyceride and cholesterol levels and decreased HDL-cholesterol, which is a risk factor for cardiovascular complications and is a major cause of death for diabetic patients. The treatment of diabetes is generally combined with pharmacotherapy, diet and exercise therapy.
The goal is to prevent and delay diabetic complications by continuously maintaining ideal blood sugar. However, since there is currently no cure for diabetes, continuous research is required for drugs and foods that can improve hyperglycemia and hyperlipidemia.
Diabetes is divided into two types, type I and type II. Type I is insulin-dependent and type II is non-insulin dependent. 당뇨병에 대한 기존의 인슐린이나 경구용 혈당 강하제의 투여로는 근원적 치료에 한계가 있기 때문에 최근에는 약물적 요법과 함께 다양한 생리활성을 갖고 있는 기능성 건강식품을 소재로한 당뇨병 예방 및 치료제로서의 가능성에 관한 연구가 시도되고 있으며 상당수의 환자들이 약물요법과 함께 운동요법과 민간요법을 시도하고 있는 것으로 나타났다 Lim, S.
The Effect of BuOH Fraction of Polygonatum odoratum with Selenium on Blood Glucose Level and Lipid Peroxidation in Streptozotocin Induced Diabetic Rats. Korean J. Nutrition, 33 7 Korean Soc. Food Sci. Nutrition, 33 7 : induced Diabetic Male Rats.
상엽 복합추출물과 운동의 병용이 스트렙토조토신 streptozotoin, STZ 에 의해 유 발된 당뇨의 혈액 내의 과산화지질의 양을 감소시킬 뿐만 아니라 간의 총 콜레스테롤의 저하에도 효과를 나타낸다고 보고 된 바 있으며 고영철, streptozotoin 당뇨 유발 흰쥐에서 상엽복합추출물과 운동이 지질대사에 미치는 영향, Korea Sport Research, , Vol.
It has been reported that the combination of lobe extract and exercise not only reduces the amount of lipid peroxide in the blood of diabetes induced by streptozotocin STZ , but also lowers the liver's total cholesterol Go Young Chul, streptozotoin.
The effect of upper lobe complex and exercise on lipid metabolism in diabetic rats, Korea Sport Research, , Vol. Antidiabetic Acupuncture Antioxidant Effect of Diet with Sea Tangle Extract, Korean Journal of Nutrition, , Vol. 또한, 백삼, 홍삼, 화기삼이 혈당강하 효과와 고혈당에 의한 체중 감소현상을 개선하며, 당뇨의 대표적인 증상인 다식과 다음 현상을 개선하였다는 보고가 있었고 박경수, 고성권, 정성현, Multiple Low Dose Streptozotoin 으로 유도된 당뇨 흰쥐에서 백삼, 홍상, 화기삼의 항당뇨 활성 비교, J.
Ginseng Res. In addition, it has been reported that white ginseng, red ginseng, and Hwagi ginseng improve the hypoglycemic effect and weight loss caused by hyperglycemia, and improve the polymorphism and the following symptoms, which are the most common symptoms of diabetes Park, Kyoung Soo, Go Sung Kwon, Jung Sung Hyun, Multiple Low Dose Streptozotoin.
Comparison of Antidiabetic Activity of White Ginseng, Red Iris and Hwagi-sam in Induced Diabetic Rats, J. has been reported to be effective in inhibiting antioxidant obesity, diet, and prevention of diabetes Kim Jin-pyo, Jeon-ju, et al.
생약제를 이용한 당뇨병 치료용 조성물에 관한 특허로는 17 종의 주생약성분, 즉 동충하초, 우황, 서홍화, 황기, 수질, 호장근, 황정, 귀전우, 산수유, 목단피, 지골피, 구기자, 백출, 창출, 황련, 갈근 및 생지황을 함유하는 당뇨병 치료용 조성물에 관한 것 한국 특허등록번호 호 , 조개나물 Ajuga multiflora Bunge 로부터 혈당 강하작용이 강하고 안전성이 매우 높은 추출물을 저렴한 유기용매를 사용하여 간단하면서도 효과적으로 추출 정제하는 방법과 이 정제된 추출물을 약학적으로 사용가능한 부형제 또는 보조제 등과 함께 단독 또는 기타의 유효 약물들과 함께 병용해서 사용하는 당뇨병 치료제 조성물에 관한 것 한국 특허등록번호 호 , 순기산 생약 복합제 즉, 후박, 대황 및 지실의 추출물을 유효성분으로 함유하고 항당뇨 활성이 우수한 당뇨병 예방 및 치료용 조성물에 관한 것 한국 특허등록번호 호 및 황련, 인삼, 지모, 단삼에서 추출한 물질을 활성성분으로 하는 당뇨병 치료제인 한방약 복합제제에 관한 것 한국 특허등록번호 호 등이 있으나, 한약재 중에 지각을 첨가하였을 경우 이 당뇨병 치료에 상승 효과가 있다는 보고는 없었다.
Patents related to the composition for treating diabetes using herbal medicines include 17 kinds of main herbal ingredients, namely Cordyceps sinensis, cow sulfur, western safflower, astragalus, water quality, Ho Jang-geun, yellow jung, guinea cow, cornus milk, bark skin, phalanges, goji berry, baekchul, creation Of diabetes mellitus, a composition for treating diabetes, rhubarb, and green liquor Korean Patent Registration No.
Related to the antidiabetic composition used in combination with them Korean Patent Registration No.
본 발명자는 지각이 스트렙토조토신 streptozotoin, STZ 으로 유발한 당뇨 흰쥐의 혈당과 동맥혈관벽에 미치는 영향을 조사하여 지각이 당뇨병을 치료하는 효과가 있음을 최초로 밝히고 본 발명을 완성하였다. The present inventors first investigated the effects of perception on the blood glucose and arterial wall of diabetic rats induced with streptozotocin STZ and completed the present invention for the first time.
본 발명의 목적은, 지각이 혈관의 내피세포 보호기능을 나타내는 효과가 있고, 당뇨의 대표적인 증상인 체중감소와 다식현상을 개선시켜주며, 혈당을 낮추어 주고, 혈관의 탄성도를 증가시켜 당뇨로 인해서 나타나는 혈관부전현상을 개선시킬 수 있는 당뇨병 치료제, 건강보조식품 및 그 조제방법을 제공하고자 함에 있다.
An object of the present invention, the perception has the effect of showing the endothelial cell protective function of the blood vessels, improve the weight loss and polymorphism, which is a typical symptom of diabetes, lower blood sugar, increase the elasticity of the blood vessels due to diabetes An object of the present invention is to provide a therapeutic agent for diabetes, a dietary supplement, and a method for preparing the same, which may improve the vascular dysfunction.
상기와 같은 목적을 위하여 본 발명은 지각을 포함하는 당뇨병 치료를 위한 약학적 조성물을 제공한다. For this purpose, the present invention provides a pharmaceutical composition for treating diabetes comprising perception. 일반적으로 본 발명에 따른 당뇨병 치료용 조성물은 임상투여시에 경구 투여가 가능하며 일반적인 의약품 제제의 형태로 사용될 수 있다. 본 발명에 따른 당뇨병 치료용 조성물은 실제 임상투여시에 경구의 여러 가지 제형으로 투여될 수 있는데, 제제화 할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다.
경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 본 발명에 따른 항염증 조성물에 적어도 하나 이상의 부형제 예를 들면, 전분, 칼슘카보네이트 Calcium carbonate , 수크로스 Sucrose 또는 락토오스 Lactose , 젤라틴 등을 섞어 조제된다.
또한 단순한 부형제 이외에 마그네슘 스티레이트 탈크 같은 윤활제들도 사용된다. 경구를 위한 액상제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제,보존제 등이 포함될 수 있다. In general, the composition for treating diabetes according to the present invention can be administered orally during clinical administration and can be used in the form of a general pharmaceutical preparation.
The composition for treating diabetes according to the present invention may be administered in various oral dosage forms during actual clinical administration, and when formulated, diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, surfactants, etc.
Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and such solid preparations include at least one excipient such as starch, calcium carbonate in the anti-inflammatory composition according to the present invention. Sucrose Sucrose or lactose Lactose , gelatin and the like are mixed and prepared.
In addition to simple excipients, lubricants such as magnesium styrate talc are also used. Oral liquid preparations include suspending agents, liquid solutions, emulsions, and syrups, and may include various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin.
보다 상세하게는 전체중량에 대하여 지각 추출물 4. More specifically, 4. It provides a pharmaceutical composition characterized by. It provides a pharmaceutical composition characterized in that the capsule is filled to contain. 본 발명의 제 2의 태양은 지각을 포함한 당뇨병 치료를 위한 식품 조성물에 관한 것이다. 본 발명에 따른 당뇨병 치료용 조성물을 식품으로 사용할 경우, 본 발명에 따른 당뇨병 치료용 조성물을 그대로 첨가하거나 다른 식품 또는 식품 성분과 함께 사용되고, 통상적인 방법에 따라 적절하게 사용될 수 있다.
상기 식품의 종류에는 특별한 제한은 없다. 상기 당뇨병 치료용 조성물을 첨가할 수 있는 식품의 예로는 각종 스프, 음료수, 차, 드링크제, 비타민 복합제, 츄잉껌, 아이스크림 및 소세지 등이 있고, 유효 성분의 혼합양은 그의 사용 목적 예방, 건강 또는 치료적 처치 에 따라 적합하게 결정될 수 있다.
A second aspect of the present invention relates to a food composition for treating diabetes, including perception. When the composition for treating diabetes according to the present invention is used as a food, the composition for treating diabetes according to the present invention may be added as it is or used together with other food or food ingredients, and may be appropriately used according to a conventional method.
There is no particular limitation on the kind of food. Examples of foods to which the composition for treating diabetes can be added include various soups, beverages, teas, drinks, vitamin complexes, chewing gums, ice creams and sausages, and the amount of the active ingredient is used for its purpose prevention, health or therapeutic treatment.
Can be suitably determined according to the treatment. 보다 상세하게는 지각 추출물 0. More specifically, crust extract 0. 아이스크림의 형태로는, 지각 추출물 0. In the form of ice cream, crust extract 0. 음료의 형태로는, 지각 추출물 0.
In the form of a beverage, 0. 소세지의 형태로는,지각 추출물 0. In the form of sausage, 0. 본 발명의 제 3의 태양은 지각으로부터 당뇨병 치료용 조성물을 제조하는 방법을 제공한다. 보다 상세하게는 지각을 열수 추출 또는 유기용매 추출하는 것을 특징으로 하는 당뇨병 치료제 제조방법을 제공한다.
More specifically, the present invention provides a method for preparing diabetes treatment, characterized in that hot water extraction or organic solvent extraction from the crust. 여과기를 통해 여과하는 단계: 및 Filtration through filter: and.
상기 여액을 감압농축한 후, 동결 건조하는 단계를 포함하는 것을 특징으로 하는 당뇨병 치료제 제조방법을 제공한다. After concentrating the filtrate under reduced pressure, it provides a method for preparing a diabetes treatment comprising the step of freeze drying. 또한, 지각 건조물 분말 0. 초음파기로 5 내지 10분간 초음파처리하는 단계; Sonicating for 5 to 10 minutes with an ultrasonic wave;.
이하 본 발명을 실시예를 통하여 자세히 설명한다. 그러나 본 발명의 실시예는 본 발명의 권리범위를 한정하는 것이 아니며, 본 발명의 권리범위는 청구범위에 의하여 정하여진다. Hereinafter, the present invention will be described in detail through examples.
However, embodiments of the present invention do not limit the scope of the present invention, the scope of the present invention is defined by the claims. It measured using the MTT method and the results are shown in Table 1 and FIG. 그러나 세포는 스트렙토조토신에 의해서 생존율이 감소하였고, 지각과 스트렙토조토신을 함께 투여한 군 및 상엽과 스트렙토조토신을 함께 투여한 군에서의 혈관내피세포 생존율은 스트렙토조토신만을 투여한 군에 비하여 그 생존율이 증가하였다.
스트렙토조토신과 상엽 및 지각을 동시에 투여한 군에서 스트렙토조토신과 상엽만을 투여한 군보다 높은 세포 생존율을 보여서 지각이 혈관의 내피세포 보호기능 효과를 보였다. There was no significant difference in the survival rate of vascular endothelial cells between normal group I , crust-treated group II , and upper lobe-administered group III.
Survival rate increased to However, the survival rate of the cells was decreased by streptozotocin, and the survival rate of vascular endothelial cells in the group treated with the crust and streptozotocin, and the group treated with the upper lobe and streptozotocin was higher than that of the group treated with streptozotocin alone.
In the group treated with streptozotocin, upper lobe and perception simultaneously, the cell survival rate was higher than that of the group receiving only streptozotocin and upper lobe. 스트렙토조토신을 0. 체중, 음용수 섭취량은 전 실험 기간을 통해서 매일 일정한 시간에 측정하였다.
Streptozotocin was dissolved in 0. Diabetes was considered higher than dL. Body weight and drinking water intake were measured at regular times every day throughout the entire experimental period. 수컷 스프레기-돌레이 쥐 Spraguee-Dawley rats, ~g 를 사용하였다. 사료와 물은 실험동안에 마음대로 섭취할 수 있도록 하였다. 동물의 보호와 취급은 기관의 지침의 최고 수준의 기준에 따라 하였다.
Male Spraye-Dawley rats g were used. Feed and water were freely consumed during the experiment. The care and handling of animals was in accordance with the highest standards of institutional guidelines. The animals were divided into 8 groups, with 15 of similar weights in a group.
Group I was normal rat control group, II was perceptual treatment in normal rat, III was upper lobe treatment in normal rat, IV was upper lobe and perception in normal rat, and V was diabetes mellitus by streptozotocin.
Induced control group VI was treated with crust in diabetic rats, VII was treated with upper lobe in diabetic rats, and VIII was treated with a mixture of upper and crust in diabetic rats.
그룹 V에서 VIII은 하룻밤 동안 신선한 0. 스트렙토조토신 주입 3일 후에, 헤파린으로 응고가 방지된 모세혈관을 사용하여 의식이 있는 쥐의 눈 뒤 신경얼기로부터 retro-orbital plexus 혈액을 채취하였고, 포도당을 분석키트로 측정하였다. Control rats Groups I II, III, IV were treated with tap water. Three days after streptozotocin injection, heparin-coagulated capillaries were used to collect blood from the retro-orbital plexus of conscious rats, and glucose was measured by analytical kits.
혼합물 처리는 스트렙토조토신 처리 12시간 전에 시작되었다. 쥐의 모든 그룹은 8주 동안의 기간동안 표준사육조건 하에 유지 되었고, 체중의 변화는 각각의 그룹에서 1주마다 기록하여, 평균을 계산하였다. Groups II and VI were orally administered with only perception, groups III and VII only with upper lobe, and groups IV and VIII with oral mixture of upper lobe and crust.
Mixture treatment was started 12 hours before streptozotocin treatment. The activities of superoxide dismutase SOD were increased in liver.
The liver histological damages of experimental diabetic mice treated with C. aurantium extract were abated in comparison with the experimental diabetic mice under light microscope observation. Conclusion: It was suggested that the extract of C.
본 발명은 vlood 추출물을 함유하는 당뇨병 Iron in environmental protection 조성물과 Ballance 유효성분으로 하는 건강보조식품 및 그 제조방법에 관한 것으로서, 지각을 포함한 당뇨병 치료를 위한 aurwntium Citrus aurantium for blood sugar balance, 식품 조성물 및 지각을 열수 추출 또는 bloood 추출하는 것을 Healthy eating for diabetics 하는 당뇨병 치료제 제조방법에 aurajtium 것이다. The present invention aursntium to a diabetic therapeutic composition containing a crust sugaar, a health Citgus using the same balancce an active ingredient, and a method for manufacturing the Citrus aurantium for blood sugar balance, wherein the pharmaceutical composition, food composition, and crust for treating diabetes including crust are extracted from hot water or extracted from an organic solvent. It relates to a method for producing diabetes treatment, characterized in that. 지각, 당뇨병 Perception, diabetes. 도 1 은 제대정맥내피세포를 배양하여 각 그룹의 세포생존율을 MTT방법을 이용하여 측정한 결과를 보인다. Figure 1 shows the results of measuring the cell viability of each group by culturing the umbilical vein endothelial cells using the MTT method. Group I on the X-axis is normal cell control group, II is normal cells treated with crust, III is normal cells treated with upper lobe, IV is normal cells treated with upper lobe and crust, V is treated with streptozotocin The control group, VI is treated with streptozotocin perception, VII is streptozotocin treated with the upper lobe, VIII is a mixture of streptozotocin and the upper lobe and the crust.
Copyright : © Tsolakou glood al. This is an Iron in environmental protection access article Surantium under the terms of Creative Commons Attribution License [CC BY 4. Lipids aurajtium absorbed in Natural energy-boosting alternatives intestines and are transported throughout the body via lipoproteins for energy, steroid production, or bile acid formation. Cholesterol, low-density lipoprotein LDL -cholesterol LDL-Ctriglycerides TGs and high-density lipoprotein HDL -cholesterol HDL-Ccontribute to these pathways. An imbalance in any of these factors, either from organic or non-organic causes, can lead to dyslipidemia 1.
Ist nicht einverstanden
Sie soll Sie sagen Sie irren sich.
Wacker, welche nötige Wörter..., der bemerkenswerte Gedanke
Ja, ich bin mit Ihnen bestimmt einverstanden